Review
Rheumatology
Jacqueline Uson, Sebastian Cruz Rodriguez-Garcia, Raul Castellanos-Moreira, Terence W. O'Neill, Michael Doherty, Mikael Boesen, Hemant Pandit, Ingrid Moller Parera, Valentina Vardanyan, Lene Terslev, Willm Uwe Kampen, Maria-Antonietta D'agostino, Francis Berenbaum, Elena Nikiphorou, Irene A. Pitsillidou, Jenny de la Torre-Aboki, Loreto Carmona, Esperanza Naredo
Summary: The study established evidence and expert opinion-based recommendations to guide health professionals using intra-articular therapies in adult patients with peripheral arthropathies. The recommendations focus on practical aspects to guide health professionals before, during, and after IAT in adult patients, covering a wide range of considerations that should be taken into account in practice.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Review
Biochemistry & Molecular Biology
Sonia Sundanum, Carl Orr, Douglas Veale
Summary: Psoriatic arthritis (PsA) is a systemic inflammatory condition with multiple clinical manifestations. Despite progress in understanding its pathobiology and emergence of targeted therapies, some patients still do not respond well to current treatments. The heterogeneous nature of the disease and varying disease activity make it challenging to devise management strategies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Rheumatology
Marc H. A. Jansen, Christien Rondaan, Geertje E. Legger, Kirsten Minden, Yosef Uziel, Natasa Toplak, Despoina Maritsi, Lotte van den Berg, Guy A. M. Berbers, Patricia Bruijning, Yona Egert, Christophe Normand, Marc Bijl, Helen E. Foster, Isabelle Kone-Paut, Carine Wouters, Angelo Ravelli, Ori Elkayam, Nicolaas M. Wulffraat, Marloes W. Heijstek
Summary: This article updates the EULAR recommendations on vaccination for pedAIIRD patients, providing guidelines on vaccination principles, special circumstances, and the safety for immunosuppressed patients.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Josef S. Smolen, Robert B. M. Landewe, Sytske Anne Bergstra, Andreas Kerschbaumer, Alexandre Sepriano, Daniel Aletaha, Roberto Caporali, Christopher John Edwards, Kimme L. Hyrich, Janet E. Pope, Savia de Souza, Tanja A. Stamm, Tsutomu Takeuchi, Patrick Verschueren, Kevin L. Winthrop, Alejandro Balsa, Joan M. Bathon, Maya H. Buch, Gerd R. Burmester, Frank Buttgereit, Mario Humberto Cardiel, Katerina Chatzidionysiou, Catalin Codreanu, Maurizio Cutolo, Alfons A. den Broeder, Khadija El Aoufy, Axel Finckh, Joao Eurico Fonseca, Jacques-Eric Gottenberg, Espen A. Haavardsholm, Annamaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B. McInnes, Eduardo F. Mysler, Peter Nash, Gyula Poor, Gorica G. Ristic, Felice Rivellese, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Nikolay Stoilov, Anja Strangfeld, Annette van der Helm-van Mil, Elsa van Duuren, Theodora P. M. Vliet Vlieland, Rene Westhovens, Desiree van der Heijde
Summary: This study provides an update on the management recommendations for rheumatoid arthritis (RA) based on the latest developments in the field. The recommendations cover various aspects including medication use, combination therapy, treatment strategies, and dose reduction. The consensus was reached on 5 overarching principles and 11 specific recommendations.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Genetics & Heredity
Alberto Floris, Mattia Congia, Elisabetta Chessa, Maria Maddalena Angioni, Matteo Piga, Alberto Cauli
Summary: Specific and high-quality evidence on the efficacy of current targeted therapies for axial disease in psoriatic arthritis (axPsA) is lacking. More studies specifically designed for axPsA and based on validated definition and outcome measures are urgently needed to provide reliable evidence.
FRONTIERS IN GENETICS
(2021)
Article
Rheumatology
Arani Vivekanantham, Dylan McGagh, Laura C. Coates
Summary: The treatment goals for PsA are to control inflammation, normalize functions, prevent complications, and tailor medication choices to individual patients. A "treat to target" approach is recommended to achieve remission or low disease activity.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY
(2021)
Review
Dermatology
Alice B. Gottlieb, Joseph F. Merola
Summary: Psoriasis is a chronic inflammatory disorder that can lead to psoriatic arthritis, a heterogeneous musculoskeletal disease causing joint damage. Early detection and intervention by dermatologists is crucial in preventing permanent joint damage from psoriatic arthritis, which often manifests after skin symptoms.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Article
Rheumatology
Sofia Ramiro, Elena Nikiphorou, Alexandre Sepriano, Augusta Ortolan, Casper Webers, Xenofon Baraliakos, Robert B. M. Landewe, Filip E. Van den Bosch, Boryana Boteva, Ann Bremander, Philippe Carron, Adrian Ciurea, Floris A. van Gaalen, Pal Geher, Lianne Gensler, Josef Hermann, Manouk de Hooge, Marketa Husakova, Uta Kiltz, Clementina Lopez-Medina, Pedro M. Machado, Helena Marzo-Ortega, Anna Molto, Victoria Navarro-Compan, Michael J. Nissen, Fernando M. Pimentel-Santos, Denis Poddubnyy, Fabian Proft, Martin Rudwaleit, Mark Telkman, Sizheng Steven Zhao, Nelly Ziade, Desiree van der Heijde
Summary: The ASAS-EULAR recommendations provide updated guidance on the management of axial spondyloarthritis, including treatment targets, non-pharmacological interventions, and the use of non-steroidal anti-inflammatory drugs (NSAIDs) as the first-line pharmacological treatment. For patients with comorbidities, the use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) is recommended. The recommendations also cover the management of extramusculoskeletal manifestations, tapering of bDMARDs, and surgical interventions.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Antonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen, Martin Aringer, Laurent Arnaud, Sang-Cheol Bae, John Boletis, Ian N. Bruce, Ricard Cervera, Andrea Doria, Thomas Doerner, Richard A. Furie, Dafna D. Gladman, Frederic A. Houssiau, Luis Sousa Ines, David Jayne, Marios Kouloumas, Laszlo Kovacs, Chi Chiu Mok, Eric F. Morand, Gabriella Moroni, Marta Mosca, Johanna Mucke, Chetan B. Mukhtyar, Gyoergy Nagy, Sandra Navarra, Ioannis Parodis, Jose M. Pego-Reigosa, Michelle Petri, Bernardo A. Pons-Estel, Matthias Schneider, Josef S. Smolen, Elisabet Svenungsson, Yoshiya Tanaka, Maria G. Tektonidou, Y. K. Onno Teng, Angela Tincani, Edward M. Vital, Ronald F. van Vollenhoven, Chris Wincup, George Bertsias, Dimitrios T. Boumpas
Summary: The EULAR recommendations for the management of systemic lupus erythematosus (SLE) have been updated based on emerging new evidence. The updated recommendations provide consensus guidance on the use of various medications and treatment strategies to control the disease, as well as recommendations for assessing treatment response and tapering therapy.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Bernhard Hellmich, Beatriz Sanchez-Alamo, Jan H. Schirmer, Alvise Berti, Daniel Blockmans, Maria C. Cid, Julia U. Holle, Nicole Hollinger, Omer Karadag, Andreas Kronbichler, Mark A. Little, Raashid A. Luqmani, Alfred Mahr, Peter A. Merkel, Aladdin J. Mohammad, Sara Monti, Chetan B. Mukhtyar, Jacek Musial, Fiona Price-Kuehne, Marten Segelmark, Y. K. Onno Teng, Benjamin Terrier, Gunnar Tomasson, Augusto Vaglio, Dimitrios Vassilopoulos, Peter Verhoeven, David Jayne
Summary: Since the publication of the EULAR recommendations for the management of AAV in 2016, several clinical trials have been conducted that have the potential to change clinical care. A systematic literature review and expert opinions were used to modify existing recommendations and create new ones. The recommendations provide updated guidance on AAV management.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Sytske Anne Bergstra, Alexandre Sepriano, Andreas Kerschbaumer, Desiree van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E. Pope, Tsutomu Takeuchi, Kimme L. Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja A. Stamm, Jan W. Schoones, Josef S. Smolen, Robert B. M. Landewe
Summary: This systematic literature review examines the efficacy, duration of use, and safety of glucocorticoids (GCs) in the management of rheumatoid arthritis (RA). The study confirms the effectiveness of GCs in treating RA, with most patients able to stop GCs within 12-24 months. However, the use of GCs also carries well-known safety risks, including osteoporotic fractures, serious infections, diabetes, and mortality.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Andreas Kerschbaumer, Alexandre Sepriano, Sytske Anne Bergstra, Josef S. Smolen, Desiree van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E. Pope, Tsutomu Takeuchi, Kimme L. Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja A. Stamm, Jan W. Schoones, Robert B. M. Landewe
Summary: This study aimed to update the evidence on the efficacy of DMARDs and provide information for the 2022 update of EULAR recommendations for RA management. A systematic literature review was conducted to investigate the efficacy of cs, b, biosimilar, and tsDMARDs in RA patients. The results showed that csDMARDs combined with short-term glucocorticoids in early RA were as effective as bDMARD+MTX combination therapy. JAK inhibitors were effective in different patient populations. Tapering of DMARDs was feasible for some patients who could maintain low disease activity or achieve remission.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Alexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, Josef S. Smolen, Desiree van der Heijde, Roberto Caporali, Christopher J. Edwards, Patrick Verschueren, Savia de Souza, Janet Pope, Tsutomu Takeuchi, Kimme Hyrich, Kevin L. Winthrop, Daniel Aletaha, Tanja Stamm, Jan W. Schoones, Robert B. M. Landewe
Summary: This study conducted a systematic literature review (SLR) to evaluate the safety of synthetic and biological disease-modifying antirheumatic drugs (DMARDs) for the management of rheumatoid arthritis (RA). The results indicated that bDMARDs were associated with an increased risk of serious infections compared to csDMARDs, while JAK inhibitors (JAKi) showed higher risk of herpes zoster infections. The risks of malignancies, major adverse cardiovascular events (MACE), and venous thromboembolism (VTE) were similar among different treatments.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Biochemistry & Molecular Biology
Ana Belen Azuaga, Julio Ramirez, Juan D. D. Canete
Summary: Psoriatic arthritis is a chronic inflammatory disease associated with psoriasis and other comorbidities. Its complex pathogenesis involves genetic predisposition, environmental factors, and immune system activation. Research has identified therapeutic targets based on immune-inflammatory pathways, but heterogeneous responses remain a challenge. Translational research and integration of omics technologies are needed to improve outcomes and identify new targets.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Rheumatology
Katerina Chavatza, Myrto Kostopoulou, Dionysis Nikolopoulos, Ourania Gioti, Konstantina Togia, Laura Andreoli, Martin Aringer, John Boletis, Andrea Doria, Frederic A. Houssiau, David Jayne, Marta Mosca, Elisabet Svenungsson, Angela Tincani, George Bertsias, Antonis Fanouriakis, Dimitrios T. Boumpas
Summary: Quality indicators (QIs) for systemic lupus erythematosus (SLE) care were developed based on European League Against Rheumatism recommendations. Adherence to recommended care was found to be 54% on average, with higher adherence in treatment-related QIs. Improvement in adherence and outcomes are needed for better care of SLE patients.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Mikhail Protopopov, Fabian Proft, Stephanie Wichuk, Pedro M. Machado, Robert G. Lambert, Ulrich Weber, Susanne Juhl Pedersen, Mikkel Ostergaard, Joachim Sieper, Martin Rudwaleit, Xenofon Baraliakos, Walter P. Maksymowych, Denis Poddubnyy
Summary: This study compares the ability of MRI and conventional radiography to detect structural lesions indicative of axSpA.
Review
Rheumatology
Casper Webers, Augusta Ortolan, Alexandre Sepriano, Louise Falzon, Xenofon Baraliakos, Robert B. M. Landewe, Sofia Ramiro, Desiree van der Heijde, Elena Nikiphorou
Summary: This study aims to provide updated evidence on the efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) for the revision of management recommendations. The results showed significant efficacy of tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i), while IL-23 inhibitors failed to demonstrate relevant effects. Observational studies are required to confirm the long-term safety of IL-17i.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Lihi Eder, Ashish J. Mathew, Philippe Carron, Heidi Bertheussen, Juan D. Canete, May Azem, Andrea Delle Sedie, Carlo Salvarani, Roberto Ranza, Ashley Elliott, Anthony Turkiewicz, Ricardo Acayaba de Toledo, Hulya Bukulmez, Maria S. Stoenoiu, Arthur M. Mandelin II, Michaela Koehm, Chris A. Lindsay, Evan Siegel, Philip J. Mease
Summary: This article summarizes existing evidence regarding pharmaceutical and nonpharmaceutical interventions for enthesitis in patients with psoriatic arthritis (PsA) to facilitate an evidence-based update of the Group for Research and Assessment in Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for PsA. The article found several classes of systemic conventional and advanced therapies and local measures were recommended for active enthesitis in patients with PsA.
JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
Casper G. Schoemaker, Dawn P. Richards, Maarten de Wit
Summary: There is a growing recognition of the importance of patient engagement and involvement in health research, especially in the field of rheumatology. Although researchers in this field acknowledge the value of patients as research partners, many still do not involve them in their research teams. This viewpoint provides practical tips for researchers and patients to match the needs for patient engagement and the potential contributions from individuals living with rheumatic disease.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Medicine, General & Internal
Joseph F. Merola, Robert Landewe, Iain B. McInnes, Philip J. Mease, Christopher T. Ritchlin, Yoshiya Tanaka, Akihiko Asahina, Frank Behrens, Dafna D. Gladman, Laure Gossec, Alice B. Gottlieb, Diamant Thaci, Richard B. Warren, Barbara Ink, Deepak Assudani, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates
Summary: This study compared the efficacy and safety of Bimekizumab with placebo in patients with active psoriatic arthritis. The results showed that Bimekizumab treatment led to superior improvements in joint and skin efficacy outcomes compared with placebo. The safety profile of Bimekizumab was consistent with previous studies.
Correction
Rheumatology
Atul Deodhar, Denis Poddubnyy, Proton Rahman, Jeorg Ermann, Tetsuya Tomita, Rebeca Bolce, Soyi Liu Leage, Andris Kronbergs, Caroline Johnson, Joana Araujo, Ann Leung, Desiree van der Heijde
JOURNAL OF RHEUMATOLOGY
(2023)
Article
Dermatology
A. Gonzalez-Cantero, W. H. Boehncke, J. De Sutter, J. L. Zamorano, J. Lambert, L. Puig
Summary: This study aims to provide dermatologists with a tool to systematize the treatment of dyslipidemia in psoriasis and aid in decision-making. The study resulted in a list of concepts and recommendations for managing cardiovascular risk and using statin therapy in moderate-severe psoriasis patients. The application of these recommendations will help dermatologists manage patients' dyslipidemia and reduce their cardiovascular risk.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Review
Rheumatology
Gabriele De Marco, Alen Zabotti, Xenofon Baraliakos, Annamaria Iagnocco, Daniel Aletaha, Paulo Gisondi, Jenny Emmel, Josef S. Smolen, Dennis G. McGonagle, Laure Gossec
Summary: A systematic literature review found that patients with psoriasis who later developed psoriatic arthritis often experienced joint pain and functional limitations. Clinical and imaging characteristics can serve as indicators for predicting the development of psoriatic arthritis. Early psoriatic arthritis is predominantly oligoarticular.
Article
Surgery
Lennard M. Wurm, Julian R. Andresen, Justyna Reinke, Denis Poddubnyy, Wolfgang Ertel, Michal W. Jagielski
Summary: In this study, we evaluated a rare case of a male patient diagnosed with juvenile idiopathic arthritis. The patient presented with atraumatic femoral head necrosis, traumatic medial femoral neck fracture, and peri-implant femoral fracture. After undergoing multiple surgical interventions, the patient's PCT and CRP infection parameters drastically increased, revealing an atypical rheumatic etiology.
JOURNAL OF SURGICAL CASE REPORTS
(2023)
Article
Rheumatology
Xenofon Baraliakos, Atul Deodhar, Desiree van der Heijde, Marina Magrey, Walter P. Maksymowych, Tetsuya Tomita, Huji Xu, Ute Massow, Carmen Fleurinck, Alicia M. Ellis, Thomas Vaux, Julie Shepherd-Smith, Alexander Marten, Lianne S. Gensler
Summary: Bimekizumab (BKZ), a monoclonal antibody that inhibits IL-17F and IL-17A, demonstrated sustained efficacy in patients with axial spondyloarthritis (axSpA) at Week 52. The dual inhibition of IL-17A and IL-17F resulted in significant improvements compared to placebo and the safety profile was consistent with previous findings.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Lotte van Ouwerkerk, Patrick Verschueren, Maarten Boers, Paul Emery, Pascal Hendrik Pieter de Jong, Robert B. M. Landewe, Willem Lems, Josef S. Smolen, Tom W. J. Huizinga, Cornelia F. Allaart, Sytske Anne Bergstra
Summary: In patients with rheumatoid arthritis (RA), the use of glucocorticoids (GC) as bridging therapy resulted in a more rapid clinical improvement and fewer changes in medication, but similar long-term GC use compared with patients who did not receive bridging therapy.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Christopher T. Ritchlin, Laura C. Coates, Iain B. Mcinnes, Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Akihiko Asahina, Laure Gossec, Alice B. Gottlieb, Richard B. Warren, Barbara Ink, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Robert B. M. Landewe
Summary: The long-term efficacy and safety of Bimekizumab (BKZ) in patients with psoriatic arthritis (PsA) was evaluated. The results showed that the efficacy of BKZ was sustained from Week 16 to Week 52, and patients who switched to BKZ treatment demonstrated similar efficacy to those who received BKZ continuously. BKZ treatment was well tolerated without any new safety signals.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Peter C. Taylor, Ernest Choy, Xenofon Baraliakos, Zoltan Szekanecz, Ricardo M. Xavier, John D. Isaacs, Sander Strengholt, Julie M. Parmentier, Ralph Lippe, Yoshiya Tanaka
Summary: Janus kinases (JAKs) are a family of cytosolic tyrosine kinases that regulate cytokine signal transduction. Several small-molecule JAK inhibitors (JAKis) are now approved for the treatment of immune-mediated inflammatory diseases. Each JAKi has a unique chemical structure, resulting in a distinctive mode of binding and pharmacological characteristics. Differences also exist in selectivity, off-target effects, and various other factors. This review discusses the pharmacological profiles of specific JAKis.
Letter
Rheumatology
Xenofon Baraliakos, Effie Pournara, Laura C. Coates, Victoria Navarro-Compan, Ricardo Blanco, Eamonn O'Brien, Barbara Schulz, Robert Landewe
Review
Rheumatology
Ennio Lubrano, Silvia Scriffignano, Kurt de Vlam, Mario Ronga, Fabio Massimo Perrotta, Rik Lories
Summary: Psoriatic arthritis (PsA) is a complex and chronic inflammatory disease that combines arthritis and psoriasis with other conditions and comorbidities. Non-pharmacological approaches such as diet modifications, improved sleep quality, and physical activity have been shown to improve the quality of life for PsA patients.